Ketosis
Conditions
Keywords
Cerebrospinal Fluid, Brain-Derived Neurotrophic Factor, Point-of-Care Testing, Ketone Bodies, Ketone body adminstration
Brief summary
It is well established that the brain is capable of consuming ketone bodies, especially during low glucose availability, e.g. fasting. Cerebral metabolism of ketone bodies depends on passage of the blood brain barrier and especially the global blood concentration of ketone bodies. Ketone bodies can be administered exogenously, and the most commonly used in clinical trials is 3-hydroxybutyrate (3-OHB). 3-OHB is carried by simple diffusion and facilitated diffusion through several monocarboxylic acid transporters (MCTs) across the blood-brain barrier. To our knowledge, no studies in human adults exist that concurrently measure 3-OHB concentrations in blood and cerebrospinal fluid (CSF) after ingestion or infusion of exogenous ketone supplementation, necessitating further study. Aims: * The 3-OHB CSF/blood ratio after oral ingestion of 30 g ketone ester - primary endpoint * The window of effect: Ketone supplementation 1 h or 2 h before CSF sampling * If concentration measurements by point-of-care testing are non-inferior to mass spectrometry * If acute 3-OHB ingestion increases plasma brain-derived neurotrophic factor (BDNF) levels
Interventions
DIETARY_SUPPLEMENTKetone Ester
Commercially available ketone ester drink (KetoneAid, Virginia, USA)
OTHERPlacebo
Taste and appearance matched noncaloric placebo drink
Sponsors
Aarhus University Hospital
University of Aarhus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* All sexes * Referred to undergo an elective lumbar puncture procedure in the outpatient clinic at Department of Neurology, Aarhus University Hospital. * Age 18-80 years * Written and oral consent
Exclusion criteria
* Referred to the clinic suspecting severe neuroinflammation * Special diet habits, including ketogenic diet, fasting, intermittent fasting etc. * Daily use of insulin or other medication affecting blood glucose and/or glucose metabolism * Not able to speak or understand Danish and/or give written and oral consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-OHB CSF/blood ratio | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| CSF 3-OHB concentrations, Mass Spectrometry | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection |
| CSF glucose concentrations | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink |
| Blood 3-OHB concentrations | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT) |
| CSF 3-OHB concentrations, POCT | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT) |
| Blood glucose concentrations | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT) |
| Plasma BDNF concentrations | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink |
| Plasma 3-OHB concentrations | 1-2 hours after ingestion | After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection |
Countries
Denmark
Outcome results
None listed